Summary of minutes of EUCAST Steering Committee Meeting
London, United Kingdom 3-4 April 2012

Attending
Dr Petra Apfalter PA EUCAST Austria
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Rafael Canton RC Clinical Data Co-ordinator Spain
Dr Christian Giske CG SRGA Sweden
Prof Gunnar Kahlmeter GK Chairperson Sweden
Prof Alasdair P. MacGowan AM BSAC United Kingdom
Prof Luis Martinez Martinez LM EUCAST Spain
Dr Johan W. Mouton JM CRG The Netherlands
Dr Robert Skov RS EUCAST Denmark
Dr Martin Steinbakk MS NWGA Norway
Prof Claude-James Soussy CS CA-SFM France

Apologies
Dr Marina Ivanova MI EUCAST Estonia

Present for section 6
Dr Maiken Caveling Arendrup MA Chair, EUCAST AFST Denmark
Dr William Hope WH Scientific Secretary, AFST UK

Present for sections 20-22
Prof Emmanuelle Cambau EC Chair of ESCMID ESGMYC France
Prof Jon Friedland JF ESCMID ESGMYC UK
Dr Marianne Depreter MD Evaluator for EMA Co-rapporteur Belgium
Dr Radu Botgros RB Scientific Administrator, EMA UK

1 Chairman’s welcome
LM and RS are new General Committee representatives on the Steering Committee. RC will take over as Chairman of EUCAST and GK will take the role of Clinical Data Co-ordinator following his appointment as ESCMID President.

2 Minutes of meeting of 30-31 January 2012 With minor corrections the minutes were accepted as a correct record.

3 Matters arising from minutes of 30-31 January 2012 (items not covered by agenda)
• A note explaining the absence of breakpoints for oral cephalosporins in sites other than UTI has been published on the website.
• A EUCAST guidance note on Stenotrophomonas maltophilia has been added to the website.
• The 1 unit benzylpenicillin susceptibility of viridians streptococci has been added to breakpoint tables, version 2.0.
• A document on direct susceptibility testing has been published on the website.

4 New agents The current status of several agents was discussed.

5 EUCAST rationale documents Drafts of outstanding documents will be updated.

6 Subcommittees
• The activities of the antifungal susceptibility testing subcommittee during the past year were reviewed and future plans discussed with the subcommittee chairperson and scientific secretary.
• The new subcommittee on detection of resistance mechanisms of clinical and/or epidemiological importance has started work.

7 Breakpoint issues
• The breakpoint table note on ampicillin/amoxicillin MIC testing for pneumococci will be revised.
• Amoxicillin-clavulanate breakpoints for Enterobacteriaceae from UTI are being considered.
• The expert rule on reporting inhibitor combinations for ESBL-producing Enterobacteriaceae will be reviewed again when ongoing clinical studies are completed.
• The expert rule on dissociated clindamycin resistance in staphylococci needs clarification.
• Fluoroquinolones breakpoints for enterococci from UTI are being discussed.
• A rationale document on sulbactam breakpoints for Acinetobacter spp. is being drafted.
• A draft table of ECOFFs for topical agents will be released for general consultation.
• The clinical significance of penA mutations in Neisseria meningitidis is being investigated.
• Use of oral β-lactams to treat H. influenzae infections is being reviewed.

8 Organisms without EUCAST breakpoints Projects on Campylobacter spp., Pasteurella multocida, Burkholderia cepacia, Actinomycetes spp., Corynebacterium spp., Yersinia enterocolitica and Pseudomonas spp. other than aeruginosa are in progress. For Legionella spp., different MICs on media with and without charcoal remain a problem.

9 EUCAST methods
• Disk diffusion documents are being translated into French.
• Screening for β-lactam resistance in H. influenzae with a benzylpenicillin 1U disk works well and is in version 2 of the breakpoint tables.
• S. aureus cefoxitin disk diffusion breakpoints distinguish mecA positive from negative isolates.
• Disk diffusion tests on a large collection of streptococci, including pneumococci, are being done as part of the continuing validation of EUCAST inhibition zone correlates against MICs.
• Resistant control strains are being considered by the resistance mechanisms subcommittee.

10 Implementation of EUCAST breakpoints Website tables listing preparedness of manufacturers are being checked for clarity.

11 EUCAST website No new information.

12 Publications
• A paper explaining ECOFFs is being prepared.
• Direct links to Expert rules and Pk/Pd papers published in CMI are on the website.
• A list of EUCAST presentations at meetings is being drafted.
• An SOP on interaction of Steering Committee with NACs has been drafted.

13 Questionnaire on dosages A draft table with dosage data is being prepared.

14 List of agents recommended for testing This is being prepared in collaboration with ESGARS.

15 ESCMID EUCAST proposals for ECCMID in Berlin 2013 will be submitted.

16 EMA Revision of the EUCAST-EMA SOP is currently the subject of internal discussions.

17 CLSI The next meeting is in June 2012.

18 ECDC There will be a teleconference on TATFAR between ECDC, CDC, EUCAST and CLSI.

19 New oxazolidinone agent A preliminary presentation of the agent was given by the company.

20-22 New anti-mycobacterial agent A presentation of the agent was given by the company and breakpoints were discussed.

23 Any other business
• A proposal to allow two additional members of the General Committee to attend each Steering Committee meeting was approved by the General Committee on 1 April 2012. A note will be prepared for the News section on the website and the procedure will be implemented in 2012.
• Retapamulin and mupirocin materials for in vitro testing are available from the manufacturer.
• A paper arguing against reporting as found for Enterobacteriaceae has been published in JAC. In response, the full argument for reporting as found will be published.

24 Next meetings
9-10 July 2012, Stockholm, Sweden; 24-25 September 2012, Madrid, Spain
11-13 November 2012, Rome, Italy; 4-5 February 2013, Brussels
30 April-1 May 2013, Berlin; 8-9 July 2013, Stockholm